| Unknown | Immunisation for Adolescents Against Serious Communicable Diseases (B Part of it NT) NCT04398849 | University of Adelaide | — |
| Unknown | Propositive (Protecting Positive People From Meningococcal Infection) Follow-up Study NCT04239430 | St George's, University of London | — |
| Unknown | Sources of COmplement in Meningococcal and Pertussis Serum Bactericidal Antibody Assays NCT04023929 | St George's, University of London | — |
| Completed | Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanc NCT03378258 | Belfast Health and Social Care Trust | — |
| Completed | Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B NCT03125616 | St George's, University of London | Phase 4 |
| Completed | South Australian Meningococcal B Vaccine Herd Immunity Study NCT03089086 | University of Adelaide | Phase 4 |
| Completed | PRIME Follow up - Quadri Meningo Vacinees NCT02811120 | Public Health England | — |
| Completed | A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy NCT02451514 | GlaxoSmithKline | Phase 2 |
| Completed | Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study NCT02287688 | GlaxoSmithKline | — |
| Completed | Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy NCT02285777 | GlaxoSmithKline | Phase 2 |
| Completed | Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry NCT02223637 | GlaxoSmithKline | — |
| Completed | Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Admin NCT02173704 | GlaxoSmithKline | Phase 3 |
| Completed | Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children NCT02141516 | Novartis | Phase 3 |
| Completed | Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents NCT02140762 | Novartis Vaccines | Phase 2 |
| Completed | Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety a NCT01992536 | Novartis Vaccines | Phase 2 |
| Completed | Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologic NCT01994629 | Novartis Vaccines | Phase 2 |
| Completed | Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adol NCT01973218 | Novartis Vaccines | Phase 3 |
| Completed | Hepatitis B Vaccination in Infants NCT01896596 | Public Health England | Phase 4 |
| Completed | A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Hea NCT01478347 | Novartis Vaccines | Phase 3 |
| Completed | Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Res NCT01823536 | Novartis Vaccines | Phase 4 |
| Completed | Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the NCT01766206 | GlaxoSmithKline | Phase 4 |
| Withdrawn | Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects 2 Years of Age and Older NCT01705379 | Novartis Vaccines | — |
| Completed | Dose-finding and Safety of 2 Intradermal MEN-ACYW135-conjugate Vaccines NCT01782066 | Leiden University Medical Center | Phase 1 / Phase 2 |
| Completed | Understanding the Immune Response to Two Different Meningitis Vaccines NCT01593514 | University of Oxford | Phase 4 |
| Completed | Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults NCT01725217 | Novartis Vaccines | Phase 3 |
| Completed | Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Ol NCT01717638 | Novartis Vaccines | Phase 3 |
| Completed | Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACW NCT01682876 | GlaxoSmithKline | Phase 3 |
| Completed | Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South NCT01642589 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Withdrawn | A Case-control Study of the Efficacy of a New Serogroup A Meningococcal Conjugate Vaccine (MenAfriVac) in Mali NCT01303211 | London School of Hygiene and Tropical Medicine | — |
| Completed | A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines W NCT01466387 | Novartis | Phase 3 |
| Completed | Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate V NCT01453348 | Novartis Vaccines | Phase 3 |
| Completed | Safety Surveillance of MenACWY-CRM Vaccine in Children NCT01452438 | Novartis Vaccines | — |
| Completed | Safety of MenACWY-CRM Vaccination in Adolescents NCT01452464 | Novartis Vaccines | — |
| Completed | Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vacci NCT01434680 | Novartis | Phase 2 |
| Completed | Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Differen NCT01423084 | Novartis | Phase 3 |
| Completed | Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Childr NCT01430611 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenAC NCT01367158 | Novartis Vaccines | Phase 2 |
| Completed | Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or NCT01345721 | Novartis Vaccines | Phase 3 |
| Completed | A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis NCT01339923 | Novartis Vaccines | Phase 3 |
| Completed | Testing the Use of Prompts to Increase Adolescent Immunization Rates NCT01984125 | University of California, Los Angeles | N/A |
| Completed | Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines NCT01270503 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in Adolescents NCT01210885 | Novartis Vaccines | Phase 2 |
| Completed | A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety NCT01274897 | Novartis Vaccines | Phase 3 |
| Completed | Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a NCT01214837 | Novartis Vaccines | Phase 3 |
| Completed | Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study NCT01148524 | Novartis Vaccines | Phase 2 / Phase 3 |
| Completed | One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Reco NCT01139021 | Novartis Vaccines | Phase 3 |
| Completed | Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose NCT01026974 | Novartis Vaccines | Phase 2 |
| Completed | A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY NCT01018732 | Novartis Vaccines | Phase 2 |
| Completed | Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses o NCT01027351 | Novartis Vaccines | Phase 2 |
| Completed | A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concom NCT01000311 | Novartis Vaccines | Phase 3 |
| Completed | Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at NCT00944034 | Novartis Vaccines | Phase 2 / Phase 3 |
| Completed | Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B NCT00847145 | Novartis Vaccines | Phase 3 |
| Completed | Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Health NCT00661713 | Novartis Vaccines | Phase 2 / Phase 3 |
| Completed | Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months NCT00601731 | Novartis Vaccines | Phase 2 |
| Completed | B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Heal NCT00488683 | Novartis Vaccines | Phase 2 |
| Completed | Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered t NCT00560313 | Novartis Vaccines | Phase 2 |
| Completed | Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, NCT00433914 | Novartis Vaccines | Phase 2 |
| Completed | Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Ye NCT00329849 | Novartis Vaccines | Phase 3 |
| Completed | Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate NCT00329901 | Novartis Vaccines | Phase 3 |
| Completed | Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adol NCT00297817 | Novartis Vaccines | Phase 2 |
| Completed | Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine NCT00254995 | Sanofi Pasteur, a Sanofi Company | — |
| Completed | 36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds NCT00728260 | Sanofi Pasteur, a Sanofi Company | — |